CHMP Opinion for Multiple Sclerosis

How Sandozā€™s Biosimilar Natalizumab Could Change the Game for MS Patients

Sandoz’s Biosimilar Natalizumab Receives Positive CHMP Opinion for Multiple Sclerosis Treatment

SG Tylor

Source – Novartis On July 24, 2023 Sandoz announced a significant milestone. The Committee for Medicinal Products for Human Use ...